Action of phenytoin, ethosuximide and of the carbidopa-L-dopa association in semi-chronic cobalt-induced epilepsy in the rat. 1977

J Scuvee-Moreau, and M Lepot, and J Brotchi, and M A Gerebtzoff, and A Dresse

A semi-chronic model of cobalt-induced experimental epilepsy in the rat was used to investigate the action of two classic anticonvulsant drugs, phenytoin and ethosuximide. Single injections of ethosuximide lead to an inhibition of the epileptic discharges. We failed to demonstrate an inhibitory effect of phenytoin after preventive administration. The carbidopa-L-dopa association was investigated owing to the inhibitory effects of dopamine and its presence in the cortex. We showed that a dose of 100 mg/kg of L-dopa combined with 25 mg/kg of carbidopa is necessary and sufficient to produce an almost complete inhibition of the discharges.

UI MeSH Term Description Entries
D007980 Levodopa The naturally occurring form of DIHYDROXYPHENYLALANINE and the immediate precursor of DOPAMINE. Unlike dopamine itself, it can be taken orally and crosses the blood-brain barrier. It is rapidly taken up by dopaminergic neurons and converted to DOPAMINE. It is used for the treatment of PARKINSONIAN DISORDERS and is usually given with agents that inhibit its conversion to dopamine outside of the central nervous system. L-Dopa,3-Hydroxy-L-tyrosine,Dopaflex,Dopar,L-3,4-Dihydroxyphenylalanine,Larodopa,Levopa,3 Hydroxy L tyrosine,L 3,4 Dihydroxyphenylalanine,L Dopa
D008297 Male Males
D010672 Phenytoin An anticonvulsant that is used to treat a wide variety of seizures. It is also an anti-arrhythmic and a muscle relaxant. The mechanism of therapeutic action is not clear, although several cellular actions have been described including effects on ion channels, active transport, and general membrane stabilization. The mechanism of its muscle relaxant effect appears to involve a reduction in the sensitivity of muscle spindles to stretch. Phenytoin has been proposed for several other therapeutic uses, but its use has been limited by its many adverse effects and interactions with other drugs. Diphenylhydantoin,Fenitoin,Phenhydan,5,5-Diphenylhydantoin,5,5-diphenylimidazolidine-2,4-dione,Antisacer,Difenin,Dihydan,Dilantin,Epamin,Epanutin,Hydantol,Phenytoin Sodium,Sodium Diphenylhydantoinate,Diphenylhydantoinate, Sodium
D002230 Carbidopa An inhibitor of DOPA DECARBOXYLASE that prevents conversion of LEVODOPA to dopamine. It is used in PARKINSON DISEASE to reduce peripheral adverse effects of LEVODOPA. It has no anti-parkinson activity by itself. Methyldopahydrazine,Carbidopa, (R)-Isomer,Carbidopa, (S)-Isomer,Lodosin,Lodosyn,MK-485,MK-486,MK 485,MK 486,MK485,MK486
D003035 Cobalt A trace element that is a component of vitamin B12. It has the atomic symbol Co, atomic number 27, and atomic weight 58.93. It is used in nuclear weapons, alloys, and pigments. Deficiency in animals leads to anemia; its excess in humans can lead to erythrocytosis. Cobalt-59,Cobalt 59
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D004347 Drug Interactions The action of a drug that may affect the activity, metabolism, or toxicity of another drug. Drug Interaction,Interaction, Drug,Interactions, Drug
D004569 Electroencephalography Recording of electric currents developed in the brain by means of electrodes applied to the scalp, to the surface of the brain, or placed within the substance of the brain. EEG,Electroencephalogram,Electroencephalograms
D005013 Ethosuximide An anticonvulsant especially useful in the treatment of absence seizures unaccompanied by other types of seizures. Ethosuccimid,Emeside,Ethylmethylsuccimide,Ethymal,Etosuximida Faes,Petnidan,Pyknolepsinum,Suksilep,Suxilep,Zarontin,Faes, Etosuximida
D006834 Hydrazines Substituted derivatives of hydrazine (formula H2N-NH2). Hydrazide

Related Publications

J Scuvee-Moreau, and M Lepot, and J Brotchi, and M A Gerebtzoff, and A Dresse
July 1991, The International journal of neuroscience,
J Scuvee-Moreau, and M Lepot, and J Brotchi, and M A Gerebtzoff, and A Dresse
August 1970, Archives internationales de pharmacodynamie et de therapie,
J Scuvee-Moreau, and M Lepot, and J Brotchi, and M A Gerebtzoff, and A Dresse
January 1995, Annals of neurology,
J Scuvee-Moreau, and M Lepot, and J Brotchi, and M A Gerebtzoff, and A Dresse
August 1975, Archives of neurology,
J Scuvee-Moreau, and M Lepot, and J Brotchi, and M A Gerebtzoff, and A Dresse
March 2020, Journal of family medicine and primary care,
J Scuvee-Moreau, and M Lepot, and J Brotchi, and M A Gerebtzoff, and A Dresse
September 1975, Postgraduate medical journal,
J Scuvee-Moreau, and M Lepot, and J Brotchi, and M A Gerebtzoff, and A Dresse
June 1975, Journal of neurology,
J Scuvee-Moreau, and M Lepot, and J Brotchi, and M A Gerebtzoff, and A Dresse
June 1973, European journal of pharmacology,
J Scuvee-Moreau, and M Lepot, and J Brotchi, and M A Gerebtzoff, and A Dresse
November 1985, Acta neurologica Scandinavica,
J Scuvee-Moreau, and M Lepot, and J Brotchi, and M A Gerebtzoff, and A Dresse
June 1997, Brain injury,
Copied contents to your clipboard!